Spotlight On... Takeda bails on obesity med Contrave, spelling trouble for maker Orexigen; Vectura inks all-stock pact for SkyePharma; Allergan launches Vraylar in the U.S.; and more...

Amid underperforming sales and an expensive outcomes trial tab, Takeda is walking away from its marketing pact with Orexigen ($OREX) for obesity therapy Contrave. Now, it'll be up to Orexigen to compete in the U.S. without the Japanese pharma's 900 reps, who helped it grab a leading slice of the pie despite third-to-market entry. But in the meantime, Orexigen is also on the hook for a cardiovascular outcomes trial that could cost up to $250 million--a tall order for the California drugmaker, which netted just $53 million in Contrave sales last year. More from FiercePharmaMarketing

@FiercePharma: Activist Ackman vows to intervene after disastrous day at Valeant. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Vertex, committed to continuous manufacturing, has Hovione build plant to complement the one it already has. Article | Follow @EricPFierce

@CarlyHFierce: I've wasted a solid part of my morning just staring at pg. 42 in disbelief. More | Follow @CarlyHFierce

> Respiratory drugmaker Vectura has agreed to buy SkyePharma in an all-stock deal that values the drugmaker at $621.9 million. Report

> Allergan ($AGN) has launched antipsychotic Vraylar in the U.S. Release

> Indian officials are working on a statutory code of conduct for pharmaceutical marketing after reports of unethical practices. Report

> Novartis' ($NVS) Entresto was cleared for marketing in Singapore, the latest country to approve the heart failure med. Report

> The journal Vaccine has yanked a "seriously flawed" and "unjustified" study that purported to find new side effects to Merck's ($MRK) HPV shot Gardasil. Report

> Bayer is setting up an East Coast innovation hub in Cambridge, MA, joining a wide array of biopharma companies looking to take advantage of the institutions and expertise there. Report

Medical Device News

@FierceMedDev: Dexcom integrates its latest CGM into the Apple Watch. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: FDA panelists to focus on use of Abbott's Absorb in small vessels during deliberations. More | Follow @VarunSaxena2

@EmilyWFierce: Good news, hep C drugmakers: VA stops rationing your pricey treatments. FiercePharmaMarketing story | Follow @EmilyWFierce

> AliveCor discloses EKG band for Apple Watch, upgrades existing a-fib app. Report

Biotech News

@FierceBiotech: MIT team demonstrates potential of cancer combo for kinase inhibitors in mice. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Biotech Lesson: Be overtly transparent. If you're hiding something bad, you're asking for it. , , etc. | Follow @JohnCFierce

> Bayer plots a dealmaking hub in the biotech boomtown of Cambridge, MA. Report

> Vectura lands $621M merger deal with SkyePharma. Story

> Takeda and Frazier back a $41M round for a new urology biotech. Article

Pharma Marketing News

> GlaxoSmithKline's nicotine franchise pairs up with smoking cessation app. Report

> Good news, hep C drugmakers: VA stops rationing your pricey treatments. More

> Getting serious about digital: Takeda walks the walk with its digital accelerator model. Story

> Takeda dumps weight loss med Contrave, leaving Orexigen in the lurch. Article

Biotech Research News

> Novartis-allied scientist at Penn creates a new CAR-T model for solid tumors. More

> HDAC/PI3K inhibitors could treat common childhood cancer. Report

> MIT team demonstrates potential of cancer combo for kinase inhibitors in mice. Story

> New insights into Parkinson's disease. Item

> HIV drug increases therapeutic window for skin cancer by slowing drug resistance. Article

Vaccines News

> Journal walks back 'seriously flawed' study critical of Merck's Gardasil. More

> Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market. Story

> Health agencies inform on Zika vaccine timeline. Report

> Valneva scores $42M supply contract with DOD. News

> Duke, NIAID track HIV evolution with eyes on creating a vaccine. Article

And Finally... Some new genetic tests are designed to show how different people metabolize different drugs, but opinions about their utility vary. Report